Salemonline Journal

Generalized Anxiety Disorder Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies – Takeda, AstraZeneca, Eli Lilly and Company, Forest Laboratories

 Breaking News
  • No posts were found

Generalized Anxiety Disorder Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies – Takeda, AstraZeneca, Eli Lilly and Company, Forest Laboratories

September 14
05:08 2022
Generalized Anxiety Disorder Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies - Takeda, AstraZeneca, Eli Lilly and Company, Forest Laboratories
DelveInsight’s “Generalized Anxiety Disorder Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Generalized Anxiety Disorder, historical and forecasted epidemiology as well as the Generalized Anxiety Disorder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Generalized Anxiety Disorder market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Generalized Anxiety Disorder pipeline products will significantly revolutionize the Generalized Anxiety Disorder market dynamics.  

 

Generalized Anxiety Disorder Overview

Generalized anxiety disorder (GAD) is recognized as the most common anxiety disorder within primary care, carrying a significant degree of comorbidity, impairment, and disability. GAD is characterized by a chronic, persistent pattern of worrying, anxiety symptoms, and tension that has a waxing and waning course, often without full remission. 

The criteria of Generalized anxiety disorder in DSM-V include the characteristics such as feeling restless, keyed up, or on edge, fatiguing easily, difficulty concentrating or the mind going blank, irritability, increased muscle tension, difficulty falling asleep, staying asleep, or restlessness. 

 

Some of the key facts of the Generalized Anxiety Disorder Market Report

  • The Generalized Anxiety Disorder market size is anticipated to grow with a significant CAGR during the study period (2019-2032)  
  • Anxiety is the most common mental disorder in the United States, affecting approximately 40 million adults 
  • The majority of adults with anxiety have a mild impairment (43.5%), 33.7% have a moderate impairment, and 22.8% have a serious impairment 
  • Anxiety disorders are more common in females than in males. Anxiety affects 23% of female adults and
  • 14% of male adults 
  • Generalized Anxiety Disorder is often unrecognized or misdiagnosed as a physical condition due to the range of clinical presentations, including somatic symptoms, and the frequent occurrence of comorbid conditions 
  • Key Generalized Anxiety Disorder Companies: Takeda, AstraZeneca, Eli Lilly and Company, Forest Laboratories, Sage Therapeutics, Biohaven Pharmaceuticals, Fabre-Kramer Pharmaceuticals, and others 
  • Key Generalized Anxiety Disorder Therapies: Vortioxetine, Duloxetine, Troriluzole, Vilazodone, Quetiapine fumarate, and others 
  • The Generalized Anxiety Disorder epidemiology based on gender analyzed that Generalized anxiety disorder (GAD) is more prevalent in females than males

 

Download a Free sample for the Generalized Anxiety Disorder Market Report 

 

Key benefits of the Generalized Anxiety Disorder Market report:

  1. Generalized Anxiety Disorder market report covers a descriptive overview and comprehensive insight of the Generalized Anxiety Disorder Epidemiology and Generalized Anxiety Disorder market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Generalized Anxiety Disorder market report provides insights on the current and emerging therapies.
  3. Generalized Anxiety Disorder market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Generalized Anxiety Disorder market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Generalized Anxiety Disorder market.

 

Discover more about therapies set to grab major Generalized Anxiety Disorder market share @ Generalized Anxiety Disorder market forecast 

 

Generalized Anxiety Disorder Epidemiology Segmentation:

The Generalized Anxiety Disorder market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Generalized Anxiety Disorder
  • Prevalent Cases of Generalized Anxiety Disorder by severity
  • Gender-specific Prevalence of Generalized Anxiety Disorder
  • Diagnosed Cases of Episodic and Chronic Generalized Anxiety Disorder 

 

Generalized Anxiety Disorder Market  

The dynamics of the Generalized Anxiety Disorder market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as EXXUA, SAGE-217, and others during the forecasted period 2019-2032. 

“Currently, only a few companies are actively involved in the development of Generalized anxiety disorder therapies, however, considering the disease burden associated with Generalized anxiety disorder, there is a dire need of novel therapies to cater the patient needs.” 

 

Download the report to understand which factors are driving Generalized Anxiety Disorder epidemiology trends @ Generalized Anxiety Disorder Epidemiological Insights 

 

Generalized Anxiety Disorder Market Strengths

  • Important progress has been made regarding understanding disease pathology, diagnosis, and treatment effects in Generalized anxiety disorder (GAD) 
  • Newborn screening for Generalized anxiety disorder (GAD) has been implemented in several countries, enabling the early detection of individuals with Fabry mutations 
  • Many therapies are under investigation in various phases of clinical trials. These include pegylated forms of α-GAL, gene therapy, and substrate reduction therapy 

 

Generalized Anxiety Disorder Therapies and Key Companies

  • Vortioxetine: Takeda
  • Duloxetine: AstraZeneca
  • Troriluzole: Eli Lilly and Company
  • Vilazodone: Forest Laboratories
  • Quetiapine fumarate: Sage Therapeutics, and others

 

Scope of the Generalized Anxiety Disorder Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Generalized Anxiety Disorder Companies: Takeda, AstraZeneca, Eli Lilly and Company, Forest Laboratories, Sage Therapeutics, Biohaven Pharmaceuticals, Fabre-Kramer Pharmaceuticals, and others
  • Key Generalized Anxiety Disorder Therapies: Vortioxetine, Duloxetine, Troriluzole, Vilazodone, Quetiapine fumarate, and others
  • Therapeutic Assessment: Generalized Anxiety Disorder current marketed and Generalized Anxiety Disorder emerging therapies
  • Generalized Anxiety Disorder Market Dynamics:  Generalized Anxiety Disorder market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Generalized Anxiety Disorder  Market Access and Reimbursement 

 

Generalized Anxiety Disorder Market Opportunities 

  • Development of a potential biomarker that allows for tracking and predicting the severity and potential progress of the disease and the effectiveness of any therapeutic intervention 
  • Relative lack of enzyme replacement therapy efficacy, partly due to antibody formation, can be alleviated by combining new oral therapy approaches 
  • Due to patients’ poor quality of life with Generalized anxiety disorder (GAD), there is significant patient willingness towards expensive therapies

 

Generalized Anxiety Disorder Market Unmet Needs

  • Challenges in diagnoses
  • Development of novel Generalized Anxiety Disorder therapies
  • Limitations in gene therapy 
  • Poor disease understanding 
  • Clinical biomarkers 

 

Table of Contents 

1. Generalized Anxiety Disorder Market Report Introduction

2. Executive Summary for Generalized Anxiety Disorder

3. SWOT analysis of Generalized Anxiety Disorder

4. Generalized Anxiety Disorder Patient Share (%) Overview at a Glance

5. Generalized Anxiety Disorder Market Overview at a Glance

6. Generalized Anxiety Disorder Disease Background and Overview

7. Generalized Anxiety Disorder Epidemiology and Patient Population

8. Country-Specific Patient Population of Generalized Anxiety Disorder 

9. Generalized Anxiety Disorder Current Treatment and Medical Practices

10. Generalized Anxiety Disorder Unmet Needs

11. Generalized Anxiety Disorder Emerging Therapies

12. Generalized Anxiety Disorder Market Outlook

13. Country-Wise Generalized Anxiety Disorder Market Analysis (2019–2032)

14. Generalized Anxiety Disorder Market Access and Reimbursement of Therapies

15. Generalized Anxiety Disorder Market drivers

16. Generalized Anxiety Disorder Market barriers

17.  Generalized Anxiety Disorder Appendix

18. Generalized Anxiety Disorder Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Generalized Anxiety Disorder treatment, visit @ Generalized Anxiety Disorder Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles